<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04054830</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT nr.: 2018-001855-10</org_study_id>
    <nct_id>NCT04054830</nct_id>
  </id_info>
  <brief_title>Steroids and/ or Non-steroidal Anti-inflammatory Drugs in the Postoperative Regime After Trabeculectomy.</brief_title>
  <acronym>SNAP</acronym>
  <official_title>Steroids and/ or Non-steroidal Anti-inflammatory Drugs in the Postoperative Regime After Trabeculectomy. An Investigator-initiated Randomized Study (The SNAP Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      PURPOSE:&#xD;
&#xD;
      Glaucoma is the leading cause of non-curable blindness globally. Patients with glaucoma will&#xD;
      get a gradual narrowing of the visual fields caused by compression at the optic nerve head&#xD;
      due to increased intraocular pressure. Thus the main preventive strategy is to reduce&#xD;
      intraocular pressure, initially by eye drops and/or laser treatment but in some patients&#xD;
      surgery is warranted. The surgical procedure (trabeculectomy) most widely performed worldwide&#xD;
      creates a path from the anterior chamber to the subconjunctival space and thereby lowers the&#xD;
      IOP by producing a more efficient drainage of the aqueous humour. Surgical success depends&#xD;
      upon controlling post-operative inflammation to ensure a functional drainage. The purpose of&#xD;
      this blinded, randomized study is to investigate which anti-inflammatory treatment provides&#xD;
      better long-term control of intra-ocular pressure (IOP) following glaucoma surgery&#xD;
      (trabeculectomy) by comparing topical NSAIDs to topical steroids. Additionally, we want to&#xD;
      explore the mechanisms behind the pathophysiology of glaucoma by evaluating retinal and optic&#xD;
      nerve head perfusion before and after IOP lowering surgery. The primary outcome is the&#xD;
      intraocular pressure 12 months after surgery measured by applanation tonometry.&#xD;
&#xD;
      MAIN HYPOTHESIS:&#xD;
&#xD;
        -  NSAIDs and steroids are equally effective in assuring long-term filtering function and&#xD;
           controlling IOP after trabeculectomy but may be associated with different risk profiles&#xD;
           and bleb morphology&#xD;
&#xD;
        -  Patients with lower post-operative IOP demonstrate less progression of visual field loss&#xD;
&#xD;
        -  Trabeculectomy lowers IOP and provides better microcirculation in and oxygenation of&#xD;
           inner retinal layers (i.e. ganglion cell layer) and the optic nerve head&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure (IOP)</measure>
    <time_frame>12 months</time_frame>
    <description>Postoperative intraocular pressure (IOP) by applanation tonometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>12 months, 24 months</time_frame>
    <description>Postoperative best corrected visual acuity in logarithm to the minimal angle of resolution (logMAR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual field</measure>
    <time_frame>12 months, 24 months</time_frame>
    <description>Postoperative changes in visual field by octopus autoperimetry. (MD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical nerve damage</measure>
    <time_frame>12 months, 24 months</time_frame>
    <description>Optical nerve damage, assessed by measuring retinal nerve fiber layer (RNFL) by peripapillary optical coherence tomography (OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical success</measure>
    <time_frame>12 months, 24 months</time_frame>
    <description>The definition of surgical success criteria is dependent on the the severity of visual field defect (MD, mean deviation of visual sensitivity compared to those expected from the age-matched normative database) glaucoma diagnosis and achievement of target pressure without the use of medication (complete success) or with the use of glaucoma medication (qualified success)&#xD;
Ocular hypertension, target &lt;25 mmHg&#xD;
MD &lt; 6 dB, target &lt; 21 mmHg&#xD;
MD 6 dB - 12 dB, target &lt;18 mmHg&#xD;
MD &gt; 12 dB, target &lt; 15 mmHg</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Topical, preservative-free NSAID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical, preservative-free steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical, preservative-free NSAID (Voltaren Ophtha 1 mg/ml, GSK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per wee</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voltaren Ophtha 1 mg/ml, GSK</intervention_name>
    <description>Voltaren Ophtha 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.</description>
    <arm_group_label>Topical, preservative-free NSAID</arm_group_label>
    <arm_group_label>Topical, preservative-free NSAID (Voltaren Ophtha 1 mg/ml, GSK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monopex 1 mg/ml, Th√©a</intervention_name>
    <description>Monopex 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.</description>
    <arm_group_label>Topical, preservative-free NSAID (Voltaren Ophtha 1 mg/ml, GSK</arm_group_label>
    <arm_group_label>Topical, preservative-free steroid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with primary open-angle glaucoma (POAG), pseudoexfoliation syndrome (PEX),&#xD;
             pigment dispersion syndrome (PDS) or ocular hypertension&#xD;
&#xD;
          -  &gt;50 years&#xD;
&#xD;
          -  Women must be postmenopausal. Women are asked if they have menstruated within the&#xD;
             preceding 12 months&#xD;
&#xD;
          -  Scheduled to undergo trabeculectomy surgery at the Department of Ophthalmology at&#xD;
             Rigshospitalet-Glostrup, Denmark&#xD;
&#xD;
          -  Informed consent to participation and ability to comply with study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to any of the contents of the pharmaceuticals (active and in-active&#xD;
             ingredients) used in the study&#xD;
&#xD;
          -  Prior intraocular surgery, except from cataract surgery. If cataract surgery has been&#xD;
             performed, it should at least be 6 months prior to surgery&#xD;
&#xD;
          -  Medical history of anterior segment dysgenesis, inflammatory/uveitic glaucoma, angle&#xD;
             closure glaucoma, neovascular glaucoma and traumatic glaucoma&#xD;
&#xD;
          -  Steroid responders&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Fertile women, i.e. women who are not menopausal and women who breastfeed&#xD;
&#xD;
          -  Patients in systemic treatment with steroid or NSAID&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniella Bach-Holm, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dpt. of Ophthalmology, Rigshospitalet-Glostrup</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology</name>
      <address>
        <city>Glostrup</city>
        <state>Capital Region,</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Afrouz Ahmadzadeh</investigator_full_name>
    <investigator_title>MD, PhD-student</investigator_title>
  </responsible_party>
  <keyword>Trabeculectomy</keyword>
  <keyword>NSAID</keyword>
  <keyword>Steroid</keyword>
  <keyword>Anti-Inflammatory Agents</keyword>
  <keyword>Anti-Inflammatory Agents, Non-Steroidal</keyword>
  <keyword>Eye Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

